Global Leading Autoimmune Specialists’ CRO

[OVERCOME CHALLENGES with PRECLINA]

EXPERIENCE  PRECLINA

Preclina has launched the EXPERIENCE PRECLINA promotion to efficiently reduce the significant cost burdens for biotechs and pharmaceutical companies in evaluating the efficacy of novel drug candidates through highly optimized experiments.

  • Acceleration of Drug Development
  • Rational Go/No-Go Decision
  • Win-Win Partnership
  • Maximizing Cost-Effectiveness

Specialists’ CRO in Autoimmune and Inflammatory Disorders

Preclina, a leading non-clinical CRO specializing in autoimmune diseases, supports global competitiveness by swiftly delivering top-quality evaluation results for biotechs and pharmaceutical companies under new drug development, securing their position in the explosively expanding market of the autoimmune disease therapeutics.

  • 아이콘

    RELIABLE

  • 아이콘

    TIME
    EFFICIENT

  • 아이콘

    COST
    EFFECTIVE

  • 아이콘

    ACCURATE

Arthritis  Research

Global Leading Service for Rheumatoid Arthritis Efficacy Evaluation and MOA Research

To facilitate the development of new drugs for rheumatoid arthritis, a prototype of chronic inflammatory disease, our scientists with over 20 years of expertise optimized the most reliable disease models. Preclina’s precise and highly reproducible test results have been recognized across diverse clients.

  • Collagen-induced
    Arthritis Model

    Robust RA Efficacy Model with High Reproducibility

    1. Global Standard System with Utmost Clinical Translatability
    2. Preclina's Validated Speed
    3. Top-Quality Test Results

  • Patient-Derived
    Cells

    Patient-Derived Cell System Accelerating License-Out

    1. Large-Scale Patient-Derived Cell Banking
    2. Removing Hurdles in LO Processes
    3. Premium Platform Services

Fibrosis  Research

Robust Efficacy Evaluation Services for Anti-Fibrosis Drug Development

Preclina has established a strong efficacy evaluation system for the
development of next-generation fibrosis therapeutics that enables
overcoming of the limitations of Nintedanib in the treatment
of pulmonary fibrosis. Discover Preclina’s potent fibrosis model portfolio!

  • Bleomycin-induced Lung
    Fibrosis Model

    Optimized Global Standard Test Models for Pulmonary Fibrosis

    1. Consistent Results in the Frequency and Severity of Lung Fibrosis
    2. Stepwise Formulated Analysis System
    3. Comprehensive Portfolio of Anti-Fibrotics Discovery

  • Bleomycin-induced Skin Fibrosis Model

    Designed with LO considerations from the Start

    1. Fibrosis Patient-Derived Cell Banking
    2. Guiding Short-Cut in LO Process
    3. Premium Platform Services

Inflammatory Skin Disease Research

Providing Discovery Service of Psoriasis and Atopic Dermatitis Therapies to Carry Forward the Global New Drug Legacy

Amid the emergence of prominent targeted antibody therapies, against inflammatory skin disorders, we offer full range disease model services encompassing from screening to confirmation.

  • Imiquimod-induced &
    IL-23-induced Psoriasis Models

    Proficient Translational Research for Psoriasis

    1. Global Standard Model for Preclinical Studies
    2. Cross-over T-helper Cell Response with Psoriasis
    3. Cost-efficient Systems Designed for Ultra Savings

  • Oxazolone &
    House Dust Mite-induced Atopic Dermatitis Models

    Key Models for Atopic Dermatitis

    1. Securing Allergen-Specific Atopic Dermatitis Model
    2. Inducing Th2 Immune Response Mimicking Atopic Dermatitis Phenotype
    3. Systemic Processes Encompassing from Screening to Confirmation

Neurological Disorders

Research and Development Aimed at Surpassing the Limitations of Clinical Treatments

Try to verify the therapeutic efficacy of candidate compounds developed to address the unmet needs in the treatment of multiple sclerosis, where brain damage continues to progress despite attempts to suppress relapsing disorders. Experience our internally established, highly reproducible efficacy pharmacology models to confirm their therapeutic efficacy

  • MOG-induced EAE Model

    Widely Accepted Models Replicating Spectrum of Multiple Sclerosis

    1. Induction of CNS Inflammation and Nerve Damage by Myelin-Targeted T-Cell Immune Response
    2. Offering Best Analytical Services Using Validated Model Systems.
    3. Best Fit for Candidate Screening Backed up by Utmost Sensitivity to Efficacy Evaluation

  • Cuprizone-induced Demyelination Model

    Demyelination Evaluation Model

    1. Model Reflecting the Phenomenon of Demyelination in Multiple Sclerosis
    2. Model System for Studying the MOA of Isolated Demyelination without Myelin Damage
    3. Mouse Model for Evaluating the Neuroprotective Efficacy

Collagen Vascular Disease Research

Optimized Service for Drug Development Leader Groups Tailored to Disease Mechanisms

Given the scarcity of clinically proven treatments, the field of
lupus pharmacology demands focused drug development
efforts. We are conducting efficacy assessments utilizing key
lupus animal models to advance lupus therapeutic development.

  • NZB/NZW F1 Lupus Model

    Timeless Spontaneous Drug Model

    1. Arising from NZB/NZW Crossbreeding, F1 Spontaneously Presents the Disease
    2. The Time-honored Classical Lupus Model
    3. Faithfully Mirroring the Phenotype of Lupus Patients

  • MRL/FasIpr Lupus Model

    Earlier Onset of More Prominent Multi-Systemic Manifestation

    1. Most Commonly Utilized in Preclinical Studies of Lupus Drugs
    2. Exuberant Lymphoproliferation with Autoantibody Expression due to Fas Gene Modification
    3. Competitive Testing Timelines

Get in touch with us to find out more
about how we can support you and your research!

Contact us